Nutra Pharma Corp (NPHC) stock
NPHCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 1/30
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $806.69KP/E –Yield –
Nutra Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nutra Pharma's operating income for the twelve months ending Jun 30, 2026 was -$1.64M. For fiscal 2025 it was -$1.46M. The highest annual figure on record is -$878.42K in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.46M | – |
| FY2024 | Dec 31, 2024 | -$878.42K | – |
| FY2023 | Dec 31, 2023 | -$886.98K | – |
| FY2022 | Dec 31, 2022 | -$1.91M | – |
| FY2021 | Dec 31, 2021 | -$1.99M | – |
| FY2020 | Dec 31, 2020 | -$924.95K | – |
| FY2019 | Dec 31, 2019 | -$1.23M | – |
| FY2018 | Dec 31, 2018 | -$1.88M | – |
| FY2017 | Dec 31, 2017 | -$1.38M | – |
| FY2016 | Dec 31, 2016 | -$2.04M | – |
| FY2015 | Dec 31, 2015 | -$5.77M | – |
| FY2014 | Dec 31, 2014 | -$2.20M | – |
| FY2013 | Dec 31, 2013 | -$2.36M | – |
| FY2012 | Dec 31, 2012 | -$2.60M | – |
| FY2011 | Dec 31, 2011 | -$3.95M | – |
| FY2010 | Dec 31, 2010 | -$3.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$435.46K | – |
| Q1 FY2026 | Mar 31, 2026 | -$379.25K | – |
| Q4 FY2025 | Dec 31, 2025 | -$465.91K | – |
| Q3 FY2025 | Sep 30, 2025 | -$356.08K | – |
| Q2 FY2025 | Jun 30, 2025 | -$290.53K | – |
| Q1 FY2025 | Mar 31, 2025 | -$349.82K | – |
| Q4 FY2024 | Dec 31, 2024 | -$178.87K | – |
| Q3 FY2024 | Sep 30, 2024 | -$184.75K | – |
| Q2 FY2024 | Jun 30, 2024 | -$219.49K | – |
| Q1 FY2024 | Mar 31, 2024 | -$295.31K | – |
| Q4 FY2023 | Dec 31, 2023 | -$140.22K | – |
| Q3 FY2023 | Sep 30, 2023 | -$165.77K | – |
| Q2 FY2023 | Jun 30, 2023 | -$182.30K | – |
| Q1 FY2023 | Mar 31, 2023 | -$398.69K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$236.52K | – |
| Q2 FY2022 | Jun 30, 2022 | -$341.09K | – |
| Q1 FY2022 | Mar 31, 2022 | -$308.42K | – |
| Q4 FY2021 | Dec 31, 2021 | -$496.22K | – |
| Q3 FY2021 | Sep 30, 2021 | -$512.31K | – |
| Q2 FY2021 | Jun 30, 2021 | -$438.71K | – |
| Q1 FY2021 | Mar 31, 2021 | -$541.20K | – |
| Q4 FY2020 | Dec 31, 2020 | -$355.22K | – |
| Q3 FY2020 | Sep 30, 2020 | -$183.75K | – |
| Q2 FY2020 | Jun 30, 2020 | -$198.87K | – |
| Q1 FY2020 | Mar 31, 2020 | -$187.10K | – |
| Q4 FY2019 | Dec 31, 2019 | -$417.93K | – |
| Q3 FY2019 | Sep 30, 2019 | -$235.18K | – |
| Q2 FY2019 | Jun 30, 2019 | -$327.85K | – |
| Q1 FY2019 | Mar 31, 2019 | -$248.94K | – |
| Q4 FY2018 | Dec 31, 2018 | -$351.31K | – |
| Q3 FY2018 | Sep 30, 2018 | -$854.25K | – |
| Q2 FY2018 | Jun 30, 2018 | -$335.85K | – |
| Q1 FY2018 | Mar 31, 2018 | -$337.46K | – |
| Q4 FY2017 | Dec 31, 2017 | -$274.94K | – |
| Q1 FY2017 | Mar 31, 2017 | -$418.05K | – |
| Q2 FY2016 | Jun 30, 2016 | -$608.79K | – |
| Q1 FY2016 | Mar 31, 2016 | -$354.61K | – |
See a number that looks wrong?